NEW YORK (GenomeWeb News) - A federal jury late last week awarded Innogenetics $7 million in damages after unanimously finding Abbott Laboratores guilty of willfully infringing an Innogenetics patent covering a method of genotyping the hepatitis C virus.
 
The judge in the case can increase the award to up to three times the $7 million determined by the jury, Innogenetics said, because Abbott was found to have willfully infringed.
 
The jury decided the case in favor of Innogenetics earlier in the month.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A research duo estimates in PLOS One the number of papers that have used misidentified cell lines.

UK's National Institute for Health and Care Excellence approves GlaxoSmithKline's SCID gene therapy despite cost.

Science reports that Brazilian researchers are petitioning for the reversal of budget cuts.

In PLOS this week: gene flow patterns in common ash, guidelines for using morpholinos in zebrafish, and more.